litlas
Log inCreate account

Mark H. Wilcox

Active 1993–2025

Also published as
Mark H Wilcox
181
Papers
36,254
Citations
96
h-index
179
i10-index

Citations

Citations per year for Mark H. Wilcox1928: 1 citations1994: 1 citations1995: 1 citations1996: 4 citations1997: 4 citations1998: 13 citations1999: 7 citations2000: 14 citations2001: 32 citations2002: 32 citations2003: 35 citations2004: 35 citations2005: 50 citations2006: 71 citations2007: 85 citations2008: 171 citations2009: 148 citations2010: 217 citations2011: 267 citations2012: 336 citations2013: 358 citations2014: 337 citations2015: 339 citations2016: 305 citations2017: 274 citations2018: 307 citations2019: 1,254 citations2020: 1,102 citations2021: 999 citations2022: 929 citations2023: 608 citations2024: 1,010 citations2025: 374 citations2026: 3 citations1929–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,248 citing papers, 24.5% of this breakdownUnited Kingdom: 1,096 citing papers, 12% of this breakdownChina: 457 citing papers, 5% of this breakdownCanada: 415 citing papers, 4.5% of this breakdownAustralia: 370 citing papers, 4% of this breakdownGermany: 369 citing papers, 4% of this breakdownFrance: 363 citing papers, 4% of this breakdownItaly: 330 citing papers, 3.6% of this breakdownNetherlands: 264 citing papers, 2.9% of this breakdownSpain: 243 citing papers, 2.7% of this breakdownSwitzerland: 205 citing papers, 2.2% of this breakdownIndia: 155 citing papers, 1.7% of this breakdown
0%24.5%Other 28.9%

Institutions

Fields

  • Medicine67.9%
  • Biochemistry, Genetics and Molecular Biology16.9%
  • Immunology and Microbiology5.2%
  • Health Professions3.7%
  • Environmental Science1.6%
  • Agricultural and Biological Sciences1.4%
  • Other3.3%

Topics

  • Clostridium difficile and Clostridium perfringens research15.5%
  • Gut microbiota and health5.6%
  • Nosocomial Infections in ICU4.7%
  • Microscopic Colitis4.6%
  • Antimicrobial Resistance in Staphylococcus3.9%
  • Antibiotic Use and Resistance3.8%
  • Other61.9%

Coauthors

All papers

Open in search
  1. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

    Authors: L. Clifford McDonald, Dale N. Gerding, Stuart Johnson, Johan Bakken, Karen C. Carroll, Susan Coffin, Erik R. Dubberke, Kevin W. Garey, Carolyn V. Gould, Ciaran Kelly, Vivian G. Loo, Julia Shaklee Sammons, Thomas J. Sandora, Mark H. Wilcox - Clinical Infectious Diseases 2017 cited by 2,652

  2. Clostridium difficile infection

    Authors: Wiep Klaas Smits, Dena Lyras, D. Borden Lacy, Mark H. Wilcox, Ed J. Kuijper - Nature Reviews Disease Primers 2016 cited by 873

  3. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults

    Authors: Stuart Johnson, Valéry Lavergne, Andrew M Skinner, Anne J Gonzales-Luna, Kevin W. Garey, Ciarán P. Kelly, Mark H. Wilcox - Clinical Infectious Diseases 2021 cited by 637

  4. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults

    Authors: Joffrey van Prehn, Elena Reigadas, Erik Vogelzang, Emilio Bouza, Adriana Hristea, Benoît Guéry, Marcela Krůtová, Torbjörn Norén, Franz Allerberger, John Coia, Abraham Goorhuis, Tessel M. van Rossen, Rogier E. Ooijevaar, Karen Burns, Bente Olesen, Sarah Tschudin‐Sutter, Mark H. Wilcox, Maria J. G. T. Vehreschild, Fidelma Fitzpatrick, Ed J. Kuijper - Clinical Microbiology and Infection 2021 cited by 602

  5. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

    Authors: Mark H. Wilcox, Dale N. Gerding, Ian R. Poxton, Ciarán P. Kelly, Richard Nathan, Thomas Birch, Oliver A. Cornely, Galia Rahav, Emilio Bouza, Christine Lee, G. Jenkin, Werner Jensen, You-Sun Kim, Junichi Yoshida, Lori Gabryelski, Alison Pedley, Karen Eves, Robert Tipping, Dalya Güriş, Nicholas A. Kartsonis, Mary-Beth Dorr - New England Journal of Medicine 2017 cited by 850

  6. Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and the environment-based spread of COVID-19

    Authors: Davey L. Jones, Marcos Quintela‐Baluja, David W. Graham, Alexander Corbishley, James E. McDonald, Shelagh K. Malham, Luke S. Hillary, Thomas R. Connor, William H. Gaze, Inês B. Moura, Mark H. Wilcox, Kata Farkas - The Science of The Total Environment 2020 cited by 430

  7. Understanding Clostridium difficile Colonization

    Authors: Monique J. T. Crobach, Jon J. Vernon, Vivian G. Loo, Ling Yuan Kong, Séverine Péchiné, Mark H. Wilcox, Ed J. Kuijper - Clinical Microbiology Reviews 2018 cited by 312

  8. Emergence and global spread of epidemic healthcare-associated Clostridium difficile

    Authors: Miao He, Fábio Miyajima, Paul Roberts, Louise Ellison, Derek Pickard, Melissa J. Martin, Thomas R. Connor, Simon R. Harris, Derek Fairley, Kathleen B. Bamford, Stephanie d’Arc, John Brazier, Derek Brown, John Coia, Gill Douce, Dale N. Gerding, Heejung Kim, Tse Hsien Koh, Haru Kato, Mitsutoshi Senoh, Tom Louie, Stephen Michell, Emma Butt, Sharon J. Peacock, Nick M Brown, Tom Riley, G. Songer, Mark H. Wilcox, Munir Pirmohamed, Ed J. Kuijper, Peter M. Hawkey, Brendan W. Wren, Gordon Dougan, Julian Parkhill, Trevor D. Lawley - Nature Genetics 2012 cited by 740

  9. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection

    Authors: Monique J. T. Crobach, Tim Planche, Catherine Eckert, Frédéric Barbut, Elisabeth M. Terveer, Olaf M. Dekkers, Mark H. Wilcox, Ed J. Kuijper - Clinical Microbiology and Infection 2016 cited by 588

  10. Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe

    Authors: Martin Hunt, Phelim Bradley, Simon Grandjean Lapierre, S Heys, Mark Thomsit, Michael B. Hall, Kerri M. Malone, Penelope Wintringer, A Sarah Walker, Daniela María Cirillo, Iñaki Comas, Maha Farhat, Philip W. Fowler, Jennifer L. Gardy, Nazir Ismail, Thomas A. Kohl, Vanessa Mathys, Matthias Merker, Stefan Niemann, Shaheed Vally Omar, Vitali Sintchenko, Grace Smith, Dick van Soolingen, Philip Supply, Sabira Tahseen, Mark H. Wilcox, Irena Arandjelović, Tim E. A. Peto, Derrick W. Crook, Zamin Iqbal - Wellcome Open Research 2019 cited by 203

  11. epic3: National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in NHS Hospitals in England

    Authors: Heather Loveday, Jennie Wilson, Robert Pratt, Mana Golsorkhi, Alison Tingle, Aggie Bak, J. Browne, Jacqui Prieto, Mark H. Wilcox - Journal of Hospital Infection 2013 cited by 1,612

  12. SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)

    Authors: Sahil Khanna, Matthew Sims, Thomas Louie, Monika Fischer, Kerry L. LaPlante, Jessica R. Allegretti, Brooke Hasson, Allyson T. Fonte, Christopher McChalicher, David S. Ege, Jessica A. Bryant, Timothy J. Straub, Christopher B. Ford, Matthew R. Henn, Elaine E. L. Wang, Lisa Von Moltke, Mark H. Wilcox - Antibiotics 2022 cited by 55

  13. Clostridium difficile infection in Europe: a hospital-based survey

    Authors: Martijn P. Bauer, Daan W. Notermans, Birgit HB van Benthem, John Brazier, Mark H. Wilcox, Maja Rupnik, Dominique L. Monnet, Jaap T. van Dissel, Ed J. Kuijper - The Lancet 2010 cited by 1,019

  14. Adaptation of the WHO Essential Medicines List for national antibiotic stewardship policy in England: being AWaRe

    Authors: Emma Budd, Emma Cramp, Mike Sharland, Kieran Hand, Philip Howard, Peter Wilson, Mark H. Wilcox, Berit Müller‐Pebody, Susan Hopkins - Journal of Antimicrobial Chemotherapy 2019 cited by 87

  15. Clostridium difficile infection: new developments in epidemiology and pathogenesis

    Authors: Maja Rupnik, Mark H. Wilcox, Dale N. Gerding - Nature Reviews Microbiology 2009 cited by 1,397

  16. Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016: a study of electronic health records

    Authors: Karina-Doris Vihta, Nicole Stoesser, Martin Llewelyn, T. Phuong Quan, T. J. Davies, Nicola Fawcett, Laura Dunn, Katie Jeffery, Christopher Butler, Gail Hayward, Monique Andersson, Marcus Morgan, Sarah Oakley, Amy M. Mason, Susan Hopkins, David Wyllie, Derrick W. Crook, Mark H. Wilcox, Alan P. Johnson, Tim Peto, A. Sarah Walker - The Lancet Infectious Diseases 2018 cited by 173

  17. A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018

    Authors: Virginie Viprey, Georgina Davis, Anthony Benson, Duncan Ewin, William Spittal, Jon J. Vernon, Maja Rupnik, Alice Banz, Florence Allantaz, Philippe Cleuziat, the COMBACTE-CDI National Coordinators, Mark H. Wilcox, Kerrie Davies - Eurosurveillance 2022 cited by 54

  18. Perturbations of the gut microbiome in anti-CCP positive individuals at risk of developing rheumatoid arthritis

    Authors: Christopher Rooney, Kulveer Mankia, Suparna Mitra, Inês B. Moura, Paul Emery, Mark H. Wilcox - Lara D. Veeken 2020 cited by 49

  19. Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile

    Authors: Abiola Olumuyiwa Olaitan, Chetna Dureja, Madison A. Youngblom, Madeline A. Topf, Wan‐Jou Shen, Anne J Gonzales-Luna, Aditi Deshpande, Kirk E. Hevener, Jane Freeman, Mark H. Wilcox, Kelli L. Palmer, Kevin W. Garey, Caitlin S. Pepperell, Julian G. Hurdle - Nature Communications 2023 cited by 56

  20. Multilocus Sequence Typing of Clostridium difficile

    Authors: David Griffiths, Warren N. Fawley, Melina Kachrimanidou, Rory Bowden, Derrick W. Crook, Rowena Fung, Tanya Golubchik, Rosalind M. Harding, Katie Jeffery, Keith A. Jolley, Richard Kirton, Tim Peto, Gareth Rees, Nicole Stoesser, Alison Vaughan, A. Sarah Walker, Bernadette Young, Mark H. Wilcox, Kate E. Dingle - Journal of Clinical Microbiology 2009 cited by 484

  21. An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones

    Authors: Maria J. G. T. Vehreschild, Annie Ducher, Thomas Louie, Oliver A. Cornely, Céline Féger, Aaron Dane, Marina Varastet, Fabien Vitry, Jean de Gunzburg, Antoine Andremont, France Mentré, Mark H. Wilcox - Journal of Antimicrobial Chemotherapy 2021 cited by 48

  22. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection

    Authors: Tim Planche, Kerrie Davies, Pietro G. Coen, John Finney, Irene M. Monahan, K. Morris, Lily O’Connor, Sarah Oakley, Cassie F. Pope, M.W.D. Wren, N. P. Shetty, Derrick W. Crook, Mark H. Wilcox - The Lancet Infectious Diseases 2013 cited by 434

  23. Antibiotic strategies in the era of multidrug resistance

    Authors: George H. Karam, Jean Chastre, Mark H. Wilcox, Jean‐Louis Vincent - Critical Care 2016 cited by 299

  24. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

    Authors: Stuart H. Cohen, Dale N. Gerding, Stuart Johnson, Ciarán P. Kelly, Vivian G. Loo, L. Clifford McDonald, Jacques Pepin, Mark H. Wilcox - Infection Control and Hospital Epidemiology 2010 cited by 2,943